CPL207-280, a Potent and Safe GPR40 Agonist for the treatment of Type 2 Diabetes

被引：2
|
作者：
Bazydlo-Guzenda, Katarzyna
Buda, Pawel
Kozlowska, Izabela
Mach, Mateusz
Teska-Kaminska, Malgorzata
Stelmach, Filip
Wasinska-Kalwa, Malgorzata
Galazka, Kinga
Dubiel, Krzysztof K.
Pieczykolan, Jerzy S.
Wieczorek, Maciej
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2333-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2333-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical efficacy of the novel GPR40 agonist CPL207-280 in neuropathy
    Jaworski, T.
    Janiszewski, M.
    Buda, P.
    Vialichka, V.
    Bazydlo-Guzenda, K.
    Mach, M.
    Galazka, K.
    Dominowski, J.
    Gorka, M.
    Salat, K.
    Popik, P.
    Dubiel, K.
    Pieczykolan, J.
    Wieczorek, M.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S107 - S107
  • [2] Discovery of CPL207-280CA, an Effective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes
    Bazydlo, Katarzyna
    Buda, Pawel
    Mach, Mateusz
    Dzida, Radoslaw
    Stelmach, Filip
    Dubiel, Krzysztof K.
    Pieczykolan, Jerzy S.
    Wieczorek, Maciej
    DIABETES, 2018, 67
  • [3] ZYDG2, a Potent, Selective, and Safe GPR40 Agonist for Treatment of Type 2 Diabetes
    Jain, Mukul R.
    Giri, Suresh R.
    Trivedi, Chitrang J.
    Bhoi, Bibhuti B.
    Rath, Akshyaya Chandan
    Rathod, Rohan Manubhai
    Sundar, Rajesh
    Bandyopadhyay, Debdutta
    Ramdhave, Rashmi
    Patel, Gautam D.
    Srivastava, Brijesh Kumar
    Desai, Ranjit C.
    DIABETES, 2018, 67
  • [4] Discovery of ZYDG2: a potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes
    Jain, Mukul R.
    Giri, Suresh R.
    Trivedi, Chitrang J.
    Bhoi, Bibhuti B.
    Rath, Akshyaya Chandan
    Rathod, Rohan M.
    Sundar, Rajesh
    Bandyopadhyay, Debdutta
    Ramdhave, Rashmi
    Patel, Gautam D.
    Srivastava, Brijesh Kumar
    Desai, Ranjit C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (04):
  • [5] Preclinical Development of IDG-164177 as a Potent GPR40 Agonist for Treatment of Type 2 Diabetes
    Yoon, Jong Min
    Kim, Dohee
    Lee, Don-Gil
    An, Kyung Mi
    Lee, Myong Jae
    Hong, Chang-Hee
    Hong, Dahae
    Kwak, Hyun-Jung
    Je, In-Gyu
    Song, Hyo-Jung
    DIABETES, 2020, 69
  • [6] Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes
    Yoon, Jongmin
    Song, Haengjin
    Kim, Jung Ho
    Lee, Seolhee
    Shin, Chorong
    Jun, Yearin
    Hong, Dahae
    Lee, Don-Gil
    Jang, Eunhye
    Kim, Jisu
    An, Kyungmi
    Hong, Chang-Hee
    Kwak, Hyun-Jung
    Je, In-Gyu
    Song, Hyo-Jung
    DIABETES, 2021, 70
  • [7] In Vitro Pharmacodynamic Studies of IDG-16177, a Potent GPR40 Agonist, for the Treatment of Type 2 Diabetes
    Yoon, Jongmin
    Song, Haengjin
    Lee, Don-Gil
    Kim, Jung Ho
    Hong, Dahae
    Shin, Chorong
    Jang, Eunhye
    Kim, Jisu
    Lee, Seolhee
    Jun, Yearin
    An, Kyungmi
    Hong, Chang-Hee
    Kwak, Hyun-Jung
    Je, In-Gyu
    Song, Hyo-Jung
    DIABETES, 2021, 70
  • [8] Novel GPR40 agonist CPL207-280CA independently improves glycaemia and mitigates neuropathic pain in diabetic rodents
    Buda, P.
    Bazydlo, K.
    Mach, M.
    Stelmach, F.
    Dzida, R.
    Dubiel, K.
    Pieczykolan, J.
    Wieczorek, M.
    DIABETOLOGIA, 2018, 61 : S327 - S327
  • [9] Discovery of ID11014A as a Novel GPR40 Agonist for the Treatment of Type 2 Diabetes
    An, Kyungmi
    Hong, Changhee
    Cui, Shuolin
    Kwak, Hyunjung
    Song, Hyojung
    Park, Joontae
    Moon, Anna
    Kim, Jeongah
    Yang, Jihun
    Lee, Jungwoo
    Yoon, Jongmin
    Lee, Myongjae
    Jeong, Donggu
    Kim, Dohee
    Lee, Dongil
    Koh, Eunji
    Shin, Jeongcheol
    Hong, Dahae
    Park, Jun-Gu
    Je, In-Gyu
    Lee, Seolhee
    Lee, Hongsub
    Park, Soobong
    Kang, Jaehoon
    DIABETES, 2017, 66 : LB40 - LB40
  • [10] In Vitro DILI Risk Assessment of IDG16177, a Potent and Selective GPR40 Agonist, for the Treatment of Type 2 Diabetes
    Yoon, Jongmin
    Song, Haengjin
    An, Kyungmi
    Hong, Chang-Hee
    Kwak, Hyun-Jung
    Song, Hyo-Jung
    DIABETES, 2022, 71
12345